Home / Stocks / Senores Pharmaceuticals L
SENORES

Senores Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,112.9

Change

+20.3 (1.86%)

Open

₹1,087.1

Prev. Close

₹1,092.6

Day High

₹1,125.3

Day Low

₹1,079.1

Volume Analysis

Traded

237,313

Delivered

124,503

Delivery %

52.46%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (29.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (114.7%)
  • •Strong 3-year revenue growth (162.5%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,178.64 ₹1,151.97 ₹1,132.44 ₹1,105.77 ₹1,086.24 ₹1,059.57 ₹1,040.04
Fibonacci ₹1,151.97 ₹1,134.32 ₹1,123.42 ₹1,105.77 ₹1,088.12 ₹1,077.22 ₹1,059.57
Camarilla ₹1,125.61 ₹1,121.37 ₹1,117.14 ₹1,105.77 ₹1,108.67 ₹1,104.43 ₹1,100.2

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+34.66%

1 Week

-8.55%

1 Month

-9.08%

3 Months

-26.46%

6 Months

+0.18%

1 Year

+34.77%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹35.02

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.14%

Net margin 19.05% × asset turnover 0.53x × equity multiplier 1.5x

Company Overview

Sector

Healthcare

Market Cap

₹5,125 Cr

P/E (TTM)

38.4

ROE

13.4%

Book Value

₹218.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.

TopFund Analysis

Senores Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Growth (100/100), while Valuation (26/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%). Strong 3-year EPS growth (114.7%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

93

Growth

100

Valuation

26

Cash Flow

40

Corporate Governance

56

Momentum

46

Institutional Ownership

42

Business Quality

81

Risk & Volatility

61

Liquidity

82

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 5.11 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 13.8% over last 3 years.
  • −Company has high debtors of 187 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Subsidiary’s Mehsana facility received PIC/S GMP certification from Ukraine’s SMDC on November 16, 2026.

Senores Pharmaceuticals Limited has informed regarding transcript of earnings conference call held on October 29, 2026

Senores Pharmaceuticals Limited has informed regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 79 102 80 101 103 114 138 162 171 175 180 192
Expenses + 64 80 59 77 77 95 104 112 121 128 126 135
Operating Profit 15 22 21 23 26 19 34 50 50 47 54 58
OPM % 19.0% 22.0% 27.0% 23.0% 25.0% 17.0% 25.0% 31.0% 29.0% 27.0% 30.0% 30.0%
Other Income + 1 2 0 2 5 12 3 5 7 18 3 9
Interest 2 3 5 5 6 5 5 6 5 8 7 9
Depreciation 3 4 4 4 4 5 6 8 8 9 10 10
Profit before tax 10 18 13 16 20 21 26 41 45 47 39 48
Tax % 31.0% 19.0% 19.0% 18.0% 20.0% 13.0% 20.0% 26.0% 25.0% 23.0% 23.0% 23.0%
Net Profit + 7 14 11 13 16 18 21 30 34 37 30 37
EPS in Rs 2 5 3 4 4 4 4 7 7 7 7 9
Raw PDF — — — — — — — — — — — —
YoY Sales growth — — — — 31 11 72 61 66 53 31 19

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 8 14 35 215 398 633 719
Expenses + 7 12 23 173 309 464 509
Operating Profit 1 2 13 42 90 168 209
OPM % 13.0% 14.0% 36.0% 19.0% 23.0% 27.0% 29.0%
Other Income + 0 0 4 3 19 47 37
Interest 0 1 2 9 22 25 30
Depreciation 1 1 2 10 17 31 37
Profit before tax 0 1 12 25 71 159 179
Tax % -110.0% 13.0% 32.0% -31.0% 17.0% 24.0% —
Net Profit + 1 1 8 33 58 122 137
EPS in Rs 0 0 3 9 13 25 29
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — — 149 507 86 59 39

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 6 28 36 174 740 888 957
Borrowings + 4 15 63 258 315 342 417
Other Liabilities + 2 8 23 160 126 328 261
Total Liabilities 15 59 131 622 1,227 1,604 1,681
Fixed Assets + 2 7 27 235 301 523 851
CWIP 3 8 34 97 172 249 31
Investments 1 15 16 0 0 4 6
Other Assets + 9 29 53 289 754 827 792
Total Assets 15 59 131 622 1,227 1,604 1,681
Equity Capital 4 9 10 31 46 46 46

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -3 -10 -1 -26 -46 62
Cash from Investing Activity + -4 -24 -48 -54 -429 -121
Cash from Financing Activity + 8 36 46 87 573 -1
Net Cash Flow 1 2 -3 8 98 -60
Free Cash Flow -6 -21 -48 -78 -203 -202
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -280 -526 3 -56 -41 45

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 45.77% → 45.81%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 38.2% 40.39% 41.03% 41.3% 41.54% 40.92% 37.78% 37.32%
Promoters 45.77% 45.78% 45.78% 45.8% 45.81% 45.82% 45.82% 45.81%
FII 4.25% 4.17% 3.66% 4.28% 3.35% 3.64% 6.62% 6.01%
DII 11.77% 9.66% 9.51% 8.62% 9.32% 9.62% 9.77% 10.85%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Senores Pharmaceuticals L (this stock) 5,125 38.4 5.11 13.4%
Morepen Lab. Ltd 5,061 26.8 3.67 5.33%
Orchid Pharma Limited 5,296 293.0 2.95 1.49%
Artemis Med Service Ltd 5,415 46.2 5.47 12.0%
Sahajanand Medical Tech L 5,427 75.6 — 10.4%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%
Iol Chem And Pharma Ltd 5,587 26.4 2.91 8.41%

Which Mutual Funds Hold Senores Pharmaceuticals L?

Frequently Asked Questions about Senores Pharmaceuticals L

Community Sentiment

What are other investors saying about Senores Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.